Cooperative Agreement U01FD008327
Award Date
9/20/24
Completion Date
8/30/27
Dollars Obligated
$1.8M
Funding Federal Agency
Center for Drug Evaluation and Research
Awarding Federal Agency
FDA Office of Acquisition and Grant Services
Federal Grant Program
93.103
Assistance Type
Cooperative Agreement
Place of Performance
Houston, TX 77030, USA
Similar Awards
The University of Florida (UF) Division of Sponsored Research was awarded a $650,000 project grant from the USDA National Institute of Food and Agriculture (NIFA) under the Agriculture and Food Research Initiative (AFRI) program. The grant will fund a 3-year research project to elucidate the biosynthesis of bioactive monoterpene indole alkaloids (MIAs) and spirooxindole alkaloids found in the Mitragyna speciosa (kratom) plant. The research aims to fill a critical knowledge gap in the...
This $433,710 federal Project Grant award was provided by the National Institutes of Health's National Center for Complementary and Integrative Health (NCCIH) under the Research and Training in Complementary and Integrative Health program (CFDA 93.213). The award aims to fund complementary and integrative research on the unique and overlapping mechanisms of action of cannabis and kratom constituents, as well as their potential synergistic effects, in mouse models of neuropathic pain,...
This federal Project Grant award, provided by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279), will fund a 5-year human laboratory study to investigate the effects of repeated cannabidiol (CBD) administration on the abuse-related and analgesic properties of smoked cannabis in healthy adult cannabis smokers. The $541,080 award will support a randomized, counterbalanced study where 72 participants will receive one of four CBD doses (0,...
This Cooperative Agreement award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), is for a $1,837,542 project titled "Targeting Treatment-Resistant OUD with Ketamine-Assisted Mindfulness-Oriented Recovery Enhancement." The project aims to investigate the safety, preliminary efficacy, and psycho-physiological mechanisms of combining the psychotherapy Mindfulness-Oriented Recovery Enhancement (MORE) with ketamine...
The federal Project Grant award R21DA057513, funded by the National Institutes of Health (NIH) Office of the Director under the Trans-NIH Research Support program (CFDA 93.310), will support research to determine the functional efficacy and selectivity of cannabidiol in ameliorating heroin-associated side effects in non-human primates. The $232,500 award will be used to investigate cannabidiol's ability to attenuate the abuse-related effects of heroin and modulate heroin-induced respiratory...
This federal Cooperative Agreement award, with a total funding amount of $100,000.00, was provided by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279). The award establishes the Resource Center for Cannabis and Cannabinoid Research (R3CR) to address the major barriers and challenges to cannabis research faced by the scientific community. The R3CR will provide guidance, information, and research support to investigators involved in...
This Cooperative Agreement award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $6,489,450.00 in funding to New York University School of Medicine to evaluate the use of psilocybin as an adjunctive treatment for opioid use disorder (OUD) in methadone-maintained patients who continue to use illicit opioids. The project will recruit 240 participants across four opioid treatment programs in New York and New Mexico,...
The federal Cooperative Agreement award U01DA059791, valued at $23,579,701.00, was provided by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279). The award supports the clinical development of PF614-MPAR, a novel opioid pain medication with built-in abuse-resistant and overdose protection features. The product combines the TAAP (Trypsin Activated Abuse Protection) oxycodone prodrug PF614 with the trypsin inhibitor nafamostat to provide...
This federal Cooperative Agreement award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $19,302,777 to Nirsum Laboratories, Inc. to accelerate the development of NRS-033 towards Phase 3 trials and FDA registration for the treatment of opioid use disorder (OUD). The key products and services to be delivered include late-stage chemistry, manufacturing, and controls (CMC) for the active pharmaceutical ingredient (API) and...
This federal Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), will fund a $268,470 research project by the RAND Corporation to study the impacts of medical cannabidiol (CBD) policies on substance use, opioid overdoses, and alcohol-related poisonings. The project aims to analyze recent changes in CBD policies and access across the U.S. and evaluate how these policies may affect the use of opioids, alcohol,...